Clara
Álvarez Villamarín
Universidad de Sevilla
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Sevilla (5)
2024
-
Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)
Nature Communications
-
Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)
Nature Communications
-
Formulation of protein-loaded nanoparticles via freeze-drying
Drug Delivery and Translational Research
-
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
Nature Communications, Vol. 15, Núm. 1
2014
-
Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF
Endocrinology, Vol. 155, Núm. 11, pp. 4329-4340